TTP Labtech Acquires Assets in Fluorescence Lifetime Technology

14 Jan 2014
Share
Significant improvements in assay reagents and availability of High Throughput Screen (HTS)-compatible readers has propelled fluorescence lifetime (FLT) technology to the vanguard of cost-effective screening technologies. TTP Labtech has consolidated its position in the field with today’s announcement of the purchase of assets from AssayMetrics Limited, Cardiff, UK a leading company in FLT.

The acquisition enhances TTP Labtech’s new ameon™ system equipped with real-time decay curve analysis (RT-DCA), licensed from Fluorescence Innovations Inc (Minneapolis, US). The ameon represents the next generation of FLT reader technology providing a combination of speed, precision, and data quality that can be readily exploited in HTS workflows.

“The development of the ameon reader introduces an exciting new dimension to FLT technology giving researchers a step-change in sample throughput and data quality,” said Dr Greg Gillispie, President of Fluorescence Innovations.

“Reception to ameon has been very positive with early feedback from beta-partners reporting superior tolerance to compound interference compared to established methodologies,” commented Dr Wayne Bowen, Chief Scientific Officer of TTP Labtech. “Increasing access to relevant instrumentation is revealing the true potential of FLT for cost critical assays to the screening community.”

For further information please click on the company website link below.

Request Info


Company website

TTP Labtech
profile photo

Sarah Thomas
Editorial Assistant